Slideshow

Hot Topics in Psoriatic Arthritis: Updates From EULAR 2018

Two recent studies focus on the risks of osteoporosis and cardiovascular disease in patients on the psoriatic arthritis/psoriasis spectrum.

References1. Freier D, Zeiner K, Biesen R, et al. Bone mineral density and fracture frequencies in patients with psoriasis or psoriasis arthritis. Presented at: EULAR 2018; June 13-16, 2018; Amsterdam, The Netherlands. Abstract AB0915.2. Camacho-Sanchez MR, Lopez-Medina C, Bautista-Aguilar L, et al. Evaluation of cardiovascular risk factors among patients with psoriasis, psoriatic arthritis and peripheral spondyloarthritis. Presented at: EULAR 2018; June 13-16, 2018; Amsterdam, The Netherlands. Abstract THU0297.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Related Content
Deucravacitinib Meets ACR20 Endpoint for Psoriatic Arthritis in Phase 3 Trial
December 24th 2024

Deucravacitinib Meets ACR20 Endpoint for Psoriatic Arthritis in Phase 3 Trial

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Edoardo Cipolletta, MD, Academic Rheumatology, School of Medicine, Nottingham City Hospital, University of Nottingham, United Kingdom,
December 19th 2024

Colchicine Prophylaxis for Gout Flares Linked to Lower Cardiovascular Events

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
HCPLive Rheumatology Month in Review
December 7th 2024

Rheumatology Month in Review: November 2024

Victoria Johnson
Natalie V. Scime, PhD, who was a Banting Postdoctoral Fellow at Institute for Clinical Evaluative Sciences (ICES) and the Department of Health and Society at the University of Toronto Scarborough
December 5th 2024

Women Who Give Birth After Infertility Have Elevated Risk of Systemic Rheumatic Disease

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.